Medicare covers the injectable drug, Reclast, when a doctor deems it medically necessary for the treatment and prevention of osteoporosis. There are specific eligibility criteria, including having ...

Reclast (zoledronic acid) is a medication that the Food and Drug Administration (FDA) has approved for preventing and treating osteoporosis in females after menopause, males, and individuals who take ...

Zoledronic acid 5 mg/100 mL bottle; solution for IV infusion. Paget’s disease of bone is characterized by greatly increased and disorderly bone remodeling. Excessive osteoclastic bone resorption is ...

Infusions might be recommended when oral medications aren’t suitable, potentially improving treatment adherence and reducing gastrointestinal side effects. Zoledronic acid and ibandronate are ...

(1) Reclast provides year-long bisphosphonate compliance with a single infusion. Reclast is the only yearly treatment approved to reduce the risk of fractures in areas of the body typically affected ...

Please provide your email address to receive an email when new articles are posted on . An annual infusion of zoledronic acid was associated with less bone loss in adults with acute spinal cord injury ...

Please provide your email address to receive an email when new articles are posted on . Published results showed integration of fracture liaison and orthopedic services, as well as inpatient ...